Filing Flows › Industrials › Pharma-Bio Serv (PBSV)
Pharma-Bio Serv (PBSV) earnings and revenue breakdown
Latest: Q3 FY26 · 10-Q filed Sep 14, 2026 · Pharma-Bio Serv (PBSV) Q3 FY26 earnings results →
Q3 FY26 Revenue up 19% year over year to $2.3M · 1¢ of every $1 of revenue lost · operating margin -3.1%
Pharma-Bio Serv made $2.3M in Q3 FY26 (+19% Y/Y). Operating margin -3.1%, net loss $14K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Sep 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.3M in Q3 FY26, up 19% year over year and down 14% from the previous quarter.
Gross margin was 29.6%, up 0.4 points from Q3 FY25. Operating costs exceeded revenue by $72K, an operating margin of -3.1%. Operating expenses fell 14% while revenue rose 19%. The quarter ended with a net loss of $14K, after a profit of $233K the previous quarter. Non-operating items added $61K, -547% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $61K (down 74% year over year). Non-cash charges added back $14K of depreciation and amortization and $9K of share-based compensation. Working capital and other items added $53K. Capital expenditures of $1K left free cash flow of $60K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 FY26 | 10-Q | Sep 14, 2026 | $2.3M | +19% | -3.1% | −$14K | $61K |
| Q2 FY26 | 10-Q | Jun 15, 2026 | $2.7M | +12% | 5.4% | $233K | −$365K |
| Q1 FY26 | 10-Q | Mar 17, 2026 | $2.3M | -7% | -4.1% | $33K | −$390K |
| Q4 FY25 | 10-K | Jan 29, 2026 | $2.1M | -8% | -6.2% | −$102 | $280K |
| Q3 FY25 | 10-Q | Sep 15, 2025 | $2.0M | -19% | -16.0% | −$204K | $237K |
| Q2 FY25 | 10-Q | Jun 16, 2025 | $2.4M | +2% | -4.1% | $95K | −$302K |
| Q4 FY24 | 10-K | Jan 29, 2025 | $2.3M | -35% | -6.6% | $16K | $78K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Pharma-Bio Serv
Pharma-Bio Serv, Inc. (“Pharma-Bio” or the “Company”) is a Delaware corporation organized on January 14, 2004. The Company operates in Puerto Rico, the United States, Europe and Brazil under the name of Pharma-Bio Serv, and is engaged in providing technical compliance consulting services to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. References to “we,” “us,” “our” and similar words in this Annual Report on Form 10-K refer to Pharma-Bio Serv, Inc. and its subsidiaries. Our website is www.pbsvinc.com. Information on our website or any other website is not part of this Annual Report on Form 10-K.
In its own words, from its 10-K, filed Jan 29, 2026.
Pharma-Bio Serv against its Services-Management Consulting Services peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +19% against the peers' median +7%. Operating margin: -3.1% against the peers' median 8.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PBSV Pharma-Bio Serv | Q3 FY26 | $2.3M | +19% | -3.1% |
| BAH Booz Allen Hamilton Holding | Q2 FY27 | $2.8B | -4% | 8.8% |
| G Genpact | Q3 2026 | $1.4B | +7% | 15.2% |
| ASTH Astrana Health | Q3 2026 | $1.0B | +7% | 3.9% |
| FCN FTI Consulting | Q3 2026 | $1.0B | +6% | 8.9% |
| HURN Huron Consulting Group | Q3 2026 | $491M | +11% | 12.0% |
| ICFI ICF International | Q3 2026 | $470M | +1% | 9.3% |
| ONT Onterris | Q3 2026 | $203M | -10% | 6.0% |
| EXPO Exponent | Q3 2026 | $174M | +18% | 24.1% |
Source: Pharma-Bio Serv 10-Q on SEC EDGAR · CIK 1304161 · Services-Management Consulting Services
More on PBSV
History
Every quarter: Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results · Q4 FY24 results